Results look outstanding to me. Excellent performance in all product areas and geographical regions, all underpinned by strong R&D. Seqirus seems to be running according to management predictions. I was interested to see (p.9 of report) that they are proceeding to Phase 3 study for CSL 112 (product to reduce cholesterol). That must have been a significant decision, since I presume that Phase 3 studies are expensive.
CSL Price at posting:
$142.07 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)